



IMAGINE...

Increasing Lab Efficiency and Treating More Patients

AFib is a worldwide epidemic affecting approximately **33 MILLION**^{1,2} and on the rise



About **50-70%** of the financial burden of AF is attributable to **HOSPITALIZATION COSTS**³



THE PERCLOSE™ PROSTYLE™ ADVANTAGE

IMMEDIATE AND DURABLE HEMOSTASIS



Can be confirmed and challenged on the table⁴ while patient is on full-dose anticoagulants.⁵



NOW AVAILABLE

for use in common femoral veins with small and large sheaths (5F-24F⁴, Max OD 29F⁷).

AMBULATION IN



↓ 1.9%

Low Major Complication Rate⁶

NO

Late Recurrences of Bleeding⁴

The use of the Perclose™ ProStyle™ Suture-Mediated Closure and Repair System can help:

INCREASE
EP Lab Efficiency

MINIMIZE
Avoidable Costs

ENHANCE
Patient Experience



Faster Hemostasis and Ambulation



Optimization of Clinical Resources



Faster Patient Turnover

- Monitoring
- Re-Bleeding
- In-Patient Stay
- Pain Medication
- Foley Catheter UTI's
- Access-Site Complications



Shorter Bed Rest and Hospital Stay



Less Pain Medication



Less Need For Foley Catheter

SOURCE: S. Verma. Adopting a Strategy of Early Ambulation and Same-Day Discharge for Atrial Fibrillation Ablation Cases - EP Lab Digest - May 2019.

That's Worth Thinking About.

Information contained herein for DISTRIBUTION in Australia and New Zealand ONLY.

©2021 Abbott. All rights reserved. MAT-2209812 v1.0

Perclose™ ProStyle™
Suture-Mediated Closure and Repair System

1. Chugh SS, et al. Circulation 2014 Worldwide Epidemiology of AF - A Global Burden of Disease Study 2010.
2. Rahman F, et al. Nat. Rev. *Cardiol.* 11, 639–654 (2014).
3. Patel NJ, et al. Global rising trends of atrial fibrillation - a major public health concern. June 2018.
4. As per Instructions for Use (IFU), patients may be ambulated 2 hours after the Perclose ProGlide SMC system procedures using 5F-8F sheaths. For sheaths > 8F, ambulation time is at the physician's discretion. Perclose ProGlide SMC System – Instructions for Use. Data on file at Abbott.
5. Mahavdaven VS, et al. Pre-closure of femoral venous access sites used for large-sized sheath insertion with the Perclose device in adults undergoing cardiac intervention.
6. Kar S, et al. The Use of the Perclose ProGlide Suture-Mediated Closure (SMC) Device for Venous Access-Site Closure up to 24F Sheaths. CRT 2018.
7. Max. OD 29F/0.378 inches/9.59 mm. Tests performed by and data on file at Abbott.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at vascular.eifu.abbott or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. This material is intended for use with healthcare professionals only.

Information contained herein for DISTRIBUTION in Australia and New Zealand ONLY.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Vascular Division of Abbott Medical Australia Pty Ltd: 299 Lane Cove Road, Macquarie Park NSW 2113. Phone: 1800 550 939
Abbott Vascular Division of Abbott Medical New Zealand Limited: Grd Flr, Bldg D, 4 Pacific Rise, Mount Wellington Auckland 1060. Phone: 0800 827 285

[™] Indicates a trademark of the Abbott Group of Companies.

www.cardiovascular.abbott/au
©2021 Abbott. All rights reserved. MAT-2209812 v1.0

